Loading stock…

Sino Biopharmaceutical Limited (1177) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Sino Biopharmaceutical Limited

1177Market cap $12BPrice $0.7

Country🇨🇳China

SectorHealthcare

IndustryPharmaceuticals

Develops and sells prescription drugs across oncology, liver disease, respiratory, and cardiovascular categories in China. It's one of the mainland's largest pharma players, with dozens of subsidiaries and a pipeline built on both generics and homegrown innovation.

In Bastion Portfolios?

52W Return-27%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+6%5

Revenue Forecast

Rev CAGR (1y)+19%8

Rev CAGR (3y)+10%7

Rev CAGR (5y)+9%7

Earnings Forecast

EPS Growth Y+1+120%10

EPS Growth Y+2-2%3

EPS Growth Y+3+13%7

Quality

Margins

EBIT Margin28%9

Net Income Margin7%4

Free Cash Flow Margin27%9

Debt

Net Debt/EBITDA-1.010

Efficiency

ROE7%3

ROA8%8

Earnings Stability44

GEAR+VERY STRONG92

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)185

P/E Ratio (Forward 3y)155

P/BV2.66

EV Multiples

EV/EBITDA Fwd69

EV/EBIT Fwd710

Yield

Free Cash Flow Yield11.0%9

Dividend Yieldna–

Momentum

Short term

1 month return-2%6

3 month return+11%9

YTD return-9%4

Mid term

Price vs 52wHigh65%3

1 year return-29%2

Long term

3 year return+111%8

5 year return+3%4

Risk Shield

Price Risk

Beta0.48

Volatility42%4

Free Cash Flow

Free Cash Flow Margin27%9

Free Cash Flow Yield11.0%9

Quality

ROCE18%8

Earnings Stability44

Net Debt/EBITDA-1.010

02Growth

Is it actually growing, and how fast?

1177Sino Biopharmaceutical

Revenue FY25$4.6B

GROWTH RATING↗

AVERAGE67 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+19%8

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+120%10

EPS growth, FY27E-2%3

EPS growth, FY28E+13%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 67% of companies worldwide.

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 6%/yr over the last 3 years and is set to grow 10%/yr from here.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

WATCH

Earnings are set to grow in step with sales (EPS about 13%/yr vs revenue 10%/yr). One year dips: EPS falls 2% in year 2.

WEAKNESSES

None flagged.

BOTTOM LINE

Reaccelerating Grower

A top-tier grower that's speeding up. The one thing to watch: the earnings path has a down year.

03Price Momentum

Is the market behind it right now?

1177Sino Biopharmaceutical

Total return Current158%

Price return Current119%

MOMENTUM RATING↗

AVERAGE45 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%6

3-month return+11%9

YTD return-9%4

MID & LONG-TERM▾SCORE

% of 52-week high65%3

1-year return-29%2

3-year return+111%8

5-year return+3%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+11%).

WATCH

Average long-term results. Multi-year returns are middling (+111% over three years and +3.1% over five), roughly average for the market.

Returns sit at the market level over the past month (-2%) and so far this year (-9%).

WEAKNESSES

It's down 29% over the past year, now 35% below its 52-week high. That is lagging the market.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Sino Biopharm. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

1177Sino Biopharmaceutical

Revenue FY25$4.6B

GROWTH RATING↗

AVERAGE67 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+19%8

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+120%10

EPS growth, FY27E-2%3

EPS growth, FY28E+13%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 67% of companies worldwide.

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 6%/yr over the last 3 years and is set to grow 10%/yr from here.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

WATCH

Earnings are set to grow in step with sales (EPS about 13%/yr vs revenue 10%/yr). One year dips: EPS falls 2% in year 2.

WEAKNESSES

None flagged.

BOTTOM LINE

Reaccelerating Grower

A top-tier grower that's speeding up. The one thing to watch: the earnings path has a down year.

03Price Momentum

Is the market behind it right now?

1177Sino Biopharmaceutical

Total return Current158%

Price return Current119%

MOMENTUM RATING↗

AVERAGE45 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%6

3-month return+11%9

YTD return-9%4

MID & LONG-TERM▾SCORE

% of 52-week high65%3

1-year return-29%2

3-year return+111%8

5-year return+3%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+11%).

WATCH

Average long-term results. Multi-year returns are middling (+111% over three years and +3.1% over five), roughly average for the market.

Returns sit at the market level over the past month (-2%) and so far this year (-9%).

WEAKNESSES

It's down 29% over the past year, now 35% below its 52-week high. That is lagging the market.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Sino Biopharm. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community